Is it possible they sign a deal now, but the deal is they don't actually do the purchase/share exchange til 2022? Allows us to keep our shares, and do this Reg A or really even several iterations of it to wipe as much debt as possible before conversion and maybe even uplist. Reg A will be a lot easier for us if we can say plainly, this thing we're selling you is *guaranteed worth $100M...
Offers certain benefits to EMOR, they can attempt to up their valuation and cash (how this is a $1.6B company I have no idea - apparently they have a major purchase order or something imminent).
And if/when we do transition over to EMOR preferred in 2022, we could continue to capture upside of the AMBS IP via some sort of preferred dividend.
(1)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links